- Home
- LIEN vs ELDN Comparison
LIEN vs ELDN Comparison
Compare LIEN & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIEN
- ELDN
- Stock Information
- Founded
- LIEN 2021
- ELDN 2004
- Country
- LIEN United States
- ELDN United States
- Employees
- LIEN N/A
- ELDN N/A
- Industry
- LIEN
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- LIEN
- ELDN Health Care
- Exchange
- LIEN NYSE
- ELDN Nasdaq
- Market Cap
- LIEN 278.9M
- ELDN 288.5M
- IPO Year
- LIEN 2022
- ELDN N/A
- Fundamental
- Price
- LIEN $12.43
- ELDN $4.29
- Analyst Decision
- LIEN
- ELDN Strong Buy
- Analyst Count
- LIEN 0
- ELDN 1
- Target Price
- LIEN N/A
- ELDN $16.00
- AVG Volume (30 Days)
- LIEN 5.0K
- ELDN 232.7K
- Earning Date
- LIEN 03-26-2025
- ELDN 03-27-2025
- Dividend Yield
- LIEN 11.13%
- ELDN N/A
- EPS Growth
- LIEN N/A
- ELDN N/A
- EPS
- LIEN 0.67
- ELDN N/A
- Revenue
- LIEN $12,681,914.00
- ELDN N/A
- Revenue This Year
- LIEN $71.81
- ELDN N/A
- Revenue Next Year
- LIEN $113.93
- ELDN N/A
- P/E Ratio
- LIEN $18.32
- ELDN N/A
- Revenue Growth
- LIEN 22.94
- ELDN N/A
- 52 Week Low
- LIEN $8.38
- ELDN $1.52
- 52 Week High
- LIEN $13.38
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- LIEN N/A
- ELDN 44.28
- Support Level
- LIEN N/A
- ELDN $4.40
- Resistance Level
- LIEN N/A
- ELDN $4.65
- Average True Range (ATR)
- LIEN 0.00
- ELDN 0.23
- MACD
- LIEN 0.00
- ELDN -0.04
- Stochastic Oscillator
- LIEN 0.00
- ELDN 8.16
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company's investment objective is to maximize risk-adjusted returns on equity for its stockholders by investing primarily in direct loans to privately held middle-market companies, with a focus on cannabis companies.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.